Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy
Article first published online: 19 AUG 2005
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 102, Issue 11, pages 861–868, November 1995
How to Cite
CLASP Collaborative Group CLASP Coordinating Centre, Radcliffe Infirmary, Oxford (1995), Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology, 102: 861–868. doi: 10.1111/j.1471-0528.1995.tb10872.x
- Issue published online: 19 AUG 2005
- Article first published online: 19 AUG 2005
- Received 18 July 1995 Accepted 23 August 1995
Objective To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation.
Design A questionnaire-based follow-up at 12 and 18 months of age of cohorts of surviving children whose mothers participated in a large randomised, double-blind placebo-controlled trial of 60 mg aspirin.
Setting United Kingdom and Ottawa, Canada.
Subjects 4168 children assessed at 12 months through information provided by general practitioners, and 4365 assessed at 18 months through a questionnaire to parents.
Main outcome measures Hospital visits in the first 18 months for congenital malformations, motor deficit, developmental delay, respiratory problems or bleeding problems; height or weight below the third centile; and delayed acquisition of certain developmental skills.
Results There were no clear differences in any of the main outcome measures, although some confidence intervals were wide.
Conclusions Although an adverse effect can not be ruled out, these findings are reassuring about the safety of low dose aspirin started after the first trimester, at least in respect of congenital malformations, major motor deficit, and severe neuromotor or developmental delay identifiable in early childhood. They provide no clear evidence of benefit. Taking into account evidence from large randomised controlled trials, the place of low-dose aspirin in pregnancy appears to be limited, although it may be beneficial for women at high risk of early onset pre-eclampsia; for them, evidence suggesting that it is not harmful is important.